Dr Rodrigo Carlessi
- Vascular and metabolic disorders
Investigating the molecular and metabolic mechanisms leading to liver cancer is Rodrigo’s main research focus at CHIRI. Liver cancer is one of the deadliest, contributing to approximately 10 per cent of all cancer-related deaths worldwide. In Australia, liver cancer prevalence is rapidly growing, with a 425 per cent increase over the past 25 years.
One of the most important risk factors for this disease, fatty liver, is a very common condition affecting an astonishing 25 per cent of the adult population. However, it is currently impossible to predict which patients will progress to develop liver cancer.
Rodrigo is using cutting-edge approaches to decipher the molecular signatures that can help determining the risk of a given patient to develop liver cancer in the future. This will allow for early intervention and, therefore, much better treatment outcomes.
Rodrigo’s recent research has also shed light on how insulin producing cells in the pancreas fail in diabetes. His contributions to this field of research have been recognized through awards from the Australian Diabetes Society and the Heart Foundation.
Research interests – liver cancer; liver progenitor cells; liver disease and regeneration; non-alcoholic fatty liver disease; metabolic syndrome; diabetes.